Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

RECRUITING

Beijing Tongren Hospital, Capital Medical University, Beijing

RECRUITING

The first Hospital of China Medical University, Shenyang

RECRUITING

The Second Hospital of Dalian Medical University, Dalian

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

RECRUITING

Yantai Yuhuangding Hospital, Yantai

NOT_YET_RECRUITING

The Affiliated Hospital Of Qingdao University, Qingdao

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

RECRUITING

Jiangxi Cancer Hospital, Nanchang

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Henan Provincial Peoples Hospital, Zhengzhou

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

RECRUITING

Guangdong Provincial Hospital of Chinese Medicine, Guangzhou

NOT_YET_RECRUITING

West China Hospital, Sichuan University, Chengdu

RECRUITING

The Second Affiliated Hospital of Xi'an Jiaotong University（Xibei Hospital）, Xi’an